Thirteen New Biospecimen Suppliers Added to iSpecimen’s Proprietary Provider Network
July 06 2023 - 7:30AM
iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”),
an online global marketplace that connects scientists requiring
biospecimens for medical research with a network of healthcare
specimen providers, today announced that the Company has added
thirteen new biospecimen suppliers to iSpecimen’s proprietary
Marketplace® throughout the first half of 2023. The addition of
these new sample providers increases the breadth and depth of
biospecimen offerings for researchers, including varying sample
types and formats that are both banked and prospectively collected.
iSpecimen’s expanded network will provide
researchers with even greater access to human biosamples within
various cancer and hematology, cardiovascular, autoimmune,
neurological, endocrine, metabolic and infectious disease
categories. Additional specimen capabilities include those for
environmental and food-based allergies, genitourinary disorders,
pediatric conditions, pregnancy including normal, high risk, and
fetal abnormalities, pulmonary and respiratory tract disorders,
skin and connective tissue disorders, and much more, to be
integrated into the platform. Notably, one sample provider offers
access to over 640,000 patients across five sites focused on
prospective collections for a wide array of disease indications.
Another provider specializes in highly characterized isolated
immune cells from healthy donors, as well as banked
antigen-specific T cells. iSpecimen also added a new supplier
focused on frozen clinical-grade cord blood, showcasing the
comprehensive offerings available within the global network.
Additionally, to support the Company’s goal of
advancing research among diverse patient populations, one of the
new suppliers exclusively sources biospecimens from African patient
pools to help improve health outcomes and advance translational and
genomics research for diseases that are prevalent in African
communities.
“As the industry’s global research and
development activities continue to evolve in complexity, it is
becoming increasingly important for researchers to have access to a
wide range of biospecimens,” said Tracy Curley, iSpecimen’s CEO.
“To address this growing need, the Company focused on efficiently
adding more specimen providers to its network that can also
contribute more thoughtful recommendations regarding specimen
requirements, which can ultimately support and expedite the drug
discovery process. The iSpecimen Marketplace’s expanded network
also helps to promote diversity among patient populations, ensuring
that no group goes underrepresented when it comes to finding
treatments for diseases.”
About iSpecimeniSpecimen
(Nasdaq: ISPC) offers an online marketplace for human biospecimens,
connecting scientists in commercial and non-profit organizations
with healthcare providers that have access to patients and
specimens needed for medical discovery. Proprietary, cloud-based
technology enables scientists to intuitively search for specimens
and patients across a federated partner network of hospitals, labs,
biobanks, blood centers and other healthcare organizations. For
more information, please visit www.ispecimen.com.
Forward Looking Statements
This press release may contain forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Such forward-looking statements are
characterized by future or conditional verbs such as "may," "will,"
"expect," "intend," "anticipate," "believe," "estimate" and
"continue" or similar words. You should read statements that
contain these words carefully because they discuss future
expectations and plans, which contain projections of future results
of operations or financial condition or state other forward-looking
information.
Forward-looking statements are predictions,
projections and other statements about future events that are based
on current expectations and assumptions and, as a result, are
subject to risks and uncertainties. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this press release, including but not limited to the
risk factors contained in the Company's filings with the Securities
and Exchange Commission, which are available for review at
www.sec.gov. Forward-looking statements speak only as of the date
they are made. New risks and uncertainties arise over time, and it
is not possible for the Company to predict those events or how they
may affect the Company. If a change to the events and circumstances
reflected in the Company's forward-looking statements occurs, the
Company's business, financial condition and operating results may
vary materially from those expressed in the Company's
forward-looking statements.
Readers are cautioned not to put undue reliance
on forward-looking statements, and the Company assumes no
obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
For further information, please contact:
Investor ContactKCSA Strategic
CommunicationsPhil Carlson / Erika Kay iSpecimen@kcsa.com
Media ContactsKCSA Strategic
CommunicationsRaquel Cona / Shana MarinoiSpecimen@kcsa.com
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Jun 2024 to Jul 2024
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Jul 2023 to Jul 2024